Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (NASDAQ: VVUS) peers Arena Pharmaceutials (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) are ticking higher following reports that major Pharmacy Benefit Manager (PBM) Express Scripts (Nasdaq: ESRX) added VIVUS' obesity pill Qsymia to its its national pharmacy formularies.
For more color, click here.
Both Arena and Orexigen are flat early.
For more color, click here.
Both Arena and Orexigen are flat early.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Uber fined $966 Million in the Netherlands for automating driver suspensions - Reuters
- Citadel has shed over 80% of aggregate risk from Situational Awareness portfolio - CNBC
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
